Details

Autor(en) / Beteiligte

• Benowitz, Neal L.
• Swan, Gary E.
• Jacob, Peyton
• Lessov‐Schlaggar, Christina N.
• Tyndale, Rachel F.

Titel

CYP2A6 genotype and the metabolism and disposition kinetics of nicotine

Ist Teil von

• Clinical pharmacology and therapeutics, 2006-11, Vol.80 (5), p.457-467

Ort / Verlag

New York, NY: Nature Publishing

Erscheinungsjahr

2006

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Background and Objective The liver enzyme cytochrome P450 (CYP) 2A6 is primarily responsible for the metabolism of nicotine. Variants in the CYP2A6 gene have been associated with altered nicotine metabolism and with effects on smoking behavior. Our objective was to determine the relationship between variant CYP2A6 genotypes and the disposition and metabolism of nicotine administered intravenously. Methods Intravenous infusions of deuterium‐labeled nicotine and cotinine were administered to 278 healthy twin volunteers, most of whom were white. They were genotyped for CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*7, CYP2A6*8, CYP2A6*9, CYP2A6*10, and CYP2A6*12. Results On the basis of the fractional clearance of nicotine to cotinine and on the plasma ratio of 3′‐hydroxycotinine to cotinine, both shown to be indicators of CYP2A6 enzymatic activity, subjects were classified into 3 groups. Group 1 included wild‐type variant CYP2A6*1/*1 (n = 215) and was assumed to have 100% activity. Group 2 included *1/*9 (n = 21) and *1/*12 (n = 12), which averaged about 80% of normal activity. Group 3 included *1/*2 (n = 10), *1/*4 (n = 2), *9/*12 (n = 3), *9/*4 (n = 2), and *9/*9 (n = 3), which averaged about 50% of normal activity. The mean total plasma clearance of nicotine (± SD) was 18.8 ± 6.0, 15.5 ± 4.9, and 11.7 ± 5.1 mL · min−1 · kg−1 in groups 1, 2, and 3, respectively, and group 1 had significantly faster clearance than group 2 (P < .05) and group 3 (P < .01). Overall, groups 2 and 3 also had lower total clearance of cotinine, had longer half‐lives for nicotine and cotinine, and excreted in the urine a greater fraction of the nicotine dose as unchanged nicotine and nicotine glucuronide and excreted less as 3′‐hydroxycotinine compared with group 1. Conclusions We provide novel pharmacokinetic and metabolic data on nicotine after systemic dosing in relation to common CYP2A6 genotypes. Our data will enhance the interpretation of CYP2A6 genotypic data as used in association studies of smoking behavior and its health consequences. Clinical Pharmacology & Therapeutics (2006) 80, 457–467; doi: 10.1016/j.clpt.2006.08.011